INCANNEX HEALTHCARE

Instrument Inactif

Communiqués Incannex Healthcare Australian S.E.

Actions

IHL

AU000000IHL8

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30/05	AQ
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	07/05	AQ
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	01/05	NE
Incannex Healthcare Inc. Quarterly Update, Q1 2024	16/04	AQ
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02	AQ
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	16/02	AQ
Clarion Clinics Open for Psychedelic-Assisted Treatments	01/02	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24/01	AQ
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	18/01	AQ
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17/01	AQ
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia	21/12	AQ
Incannex Healthcare : Change in Certifying Accountants - Form 8-K	15/12	PU
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	06/12	AQ
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors	17/08/22	GL
Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion	10/05/22	PR
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M	28/04/22	PR
Incannex to Acquire APIRx Pharmaceuticals USA, LLC	24/03/22	PR
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies	10/03/22	PR
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics	03/03/22	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Sécurisez et Augmentez les Rendements de vos Investissements grâce à l'Accompagnement de Nos Experts

Sécuriser mes Investissements

fermer